– Norgine B.V. today announced that the Federal agency for medicines and health products and the Danish Medicines Agency have granted marketing authorisation for PLENVUR (NER1006) for bowel cleansing in adults prior to any procedure requiring a clean bowel. The approval was granted under the European Medicines Agency decentralised procedure, with the UK as reference state. Norgine anticipates further marketing approvals in Q4 2017 and 2018.
(Logo: http://mma.prnewswire.com/media/597589/Norgine_Logo.jpg )
PLENVUR will be launched in early 2018 in Belgium and Denmark. PLENVUR is already available in the UK.
PLENVUR is a novel, low volume (1-litre) polyethylene glycol (PEG) 3350-based bowel preparation that has been developed by Norgine to provide whole bowel cleansing, shown to be superior in providing high-quality cleansing in the colon ascendens, an important area for adenoma detection.[2]
The approval was based on data from the Phase III clinical trial programme, consisting of three multicentre, randomised, parallel group studies:
Norgine manufactures PLENVUR and commercialises the product through its infrastructure in Europe and Australia and through its commercial partners in the rest of the world.
References
[1] Bisschops R, et al. P0179. Efficacy and safety of the novel 1L PEG and ascorbate bowel preparation NER1006 versus standard 2L PEG with ascorbate in overnight or morning split-dosing administration: results from the phase 3 study MORA. UEG Journal 2016; 4(5S): A218 – A219.
[2] Lasisi F, et al. Expert Rev Gastroenterol Hepatol 2011; 5(6): 745-754.
Media Contact:Isabelle Jouin, T: +44(0)1895-453643 Follow us @norgine
(Immediapress – Adnkronos
Immediapress e’ un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall’ente che lo emette. Padovanews non e’ responsabile per i contenuti dei comunicati trasmessi.)